Day 4
- Proffered paper sessions
- Challenges in oncogene addicted NSCLC
- Does Immunotherapy cure advanced cancer?
- Impact of tumor heterogeneity on precision medicine in kidney and bladder cancers
- Immuno-biology in prostate cancer
- Industry satellite symposium
- Presidential Symposium
- Management of brain metastases
- Cancer evolution and metastasis: From single cells to population dynamics
- Update on new therapies for triple negative breast cancer (TNBC)
- Treatment of young women with breast cancer
- Poster discussion sessions
- Are grade III/IV toxicities the only ones that matter?
- Treating your patients using epigenetics
- Emerging topics in developmental therapeutics
- B cell receptor as a therapeutic agent
- Neuroendocrine neoplasms of the gastro-enteropancreatic system: From the bench to the bed
- Lung cancer screening
- Emergency topics in developmental therapeutics
- Clinical challenges in head and neck cancer
- Do we need to test for PD-L1 and how do we choose?
- Access to innovative drugs in the EU
- Management of MO patient with rising PSA
- Hpw to best mange ologometastatic disease
- ESMO-ESOI Hoint Symposium: Colerectal cancer imaging-New opportunities to guide treatment decisions
- The “Micro Economics” of cancer. How the medical oncologist should micro-manage limited resources
- Management of MO patient with rising PSA
- The new EU clinical trials and data protection regulations
- Management of typical and atypical lung neuroendocrine tumors
- Critically ill cancer patients: Patient selection for admission to ICU
- Fellowships in Europe: educational oppurtunities for young oncologists
- The HANS KEULEN MEMORIAL DEBATE
- Your choice of career path in oncology